The liver plays an important role in the development of atherogenic dyslipidemia, since changes in lipid metabolism begin at the hepatocyte level. Given the prevalence of dyslipidemias and their proven effect on the development of thrombotic cardiovascular complications in patients with non-alcoholic fatty liver disease (NAFLD), it is important to understand the role of platelets and hemostatic blood activity. Objective - to determine the state of platelet-plasma hemostasis in patients with essential hypertension, with concomitant non-alcoholic fatty liver disease.
View Article and Find Full Text PDF